Inositol polyphosphate 5-phosphatase OCRL
From Proteopedia
(Difference between revisions)
Line 29: | Line 29: | ||
At a region towards the C-terminus there is a catalytically inactive Rho-GAP-like domain. It shows homology to the Rho-GAP domain found in proteins that bind and stimulate the GTPase activity of the Rho family proteins. The two reasons why this domain has no GTPase stimulating activity are: the replacement of the catalytic Arg by His and absence of a helix.<ref name="role">PMID: 17765681</ref> The ASH-RhoGAP module mediates the interactions of OCRL1 with proteins that promote specific targeting to various cellular destinations such as early endosomes, Golgi complex, lysosomes and primary cilium.<ref name="Lowe and Dent">PMID: 28669993</ref> Since these two function as a single folding module, a destabilization in one of them will affect the stability of the other. <ref name="role"/> | At a region towards the C-terminus there is a catalytically inactive Rho-GAP-like domain. It shows homology to the Rho-GAP domain found in proteins that bind and stimulate the GTPase activity of the Rho family proteins. The two reasons why this domain has no GTPase stimulating activity are: the replacement of the catalytic Arg by His and absence of a helix.<ref name="role">PMID: 17765681</ref> The ASH-RhoGAP module mediates the interactions of OCRL1 with proteins that promote specific targeting to various cellular destinations such as early endosomes, Golgi complex, lysosomes and primary cilium.<ref name="Lowe and Dent">PMID: 28669993</ref> Since these two function as a single folding module, a destabilization in one of them will affect the stability of the other. <ref name="role"/> | ||
- | |||
=== Function === | === Function === |
Revision as of 08:14, 28 April 2021
OCRL-1 mutations causing Lowe syndrome
|
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Lewis RA, Nussbaum RL, Brewer ED. Lowe Syndrome PMID:20301653
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Bokenkamp A, Ludwig M. The oculocerebrorenal syndrome of Lowe: an update. Pediatr Nephrol. 2016 Dec;31(12):2201-2212. doi: 10.1007/s00467-016-3343-3. Epub , 2016 Mar 24. PMID:27011217 doi:http://dx.doi.org/10.1007/s00467-016-3343-3
- ↑ 3.0 3.1 3.2 Kenworthy L, Charnas L. Evidence for a discrete behavioral phenotype in the oculocerebrorenal syndrome of Lowe. Am J Med Genet. 1995 Nov 20;59(3):283-90. doi: 10.1002/ajmg.1320590304. PMID:8599350 doi:http://dx.doi.org/10.1002/ajmg.1320590304
- ↑ Mao Y, Balkin DM, Zoncu R, Erdmann KS, Tomasini L, Hu F, Jin MM, Hodsdon ME, De Camilli P. A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism. EMBO J. 2009 Jul 8;28(13):1831-42. Epub 2009 Jun 18. PMID:19536138 doi:10.1038/emboj.2009.155
- ↑ Lowe M. Structure and function of the Lowe syndrome protein OCRL1. Traffic. 2005 Sep;6(9):711-9. doi: 10.1111/j.1600-0854.2005.00311.x. PMID:16101675 doi:http://dx.doi.org/10.1111/j.1600-0854.2005.00311.x
- ↑ Pirruccello M, De Camilli P. Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL. Trends Biochem Sci. 2012 Apr;37(4):134-43. doi: 10.1016/j.tibs.2012.01.002. Epub , 2012 Feb 28. PMID:22381590 doi:http://dx.doi.org/10.1016/j.tibs.2012.01.002
- ↑ Perdomo-Ramirez A, Anton-Gamero M, Rizzo DS, Trindade A, Ramos-Trujillo E, Claverie-Martin F. Two new missense mutations in the protein interaction ASH domain of OCRL1 identified in patients with Lowe syndrome. Intractable Rare Dis Res. 2020 Nov;9(4):222-228. doi: 10.5582/irdr.2020.03092. PMID:33139981 doi:http://dx.doi.org/10.5582/irdr.2020.03092
- ↑ 8.0 8.1 8.2 8.3 Erdmann KS, Mao Y, McCrea HJ, Zoncu R, Lee S, Paradise S, Modregger J, Biemesderfer D, Toomre D, De Camilli P. A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway. Dev Cell. 2007 Sep;13(3):377-90. PMID:17765681 doi:http://dx.doi.org/10.1016/j.devcel.2007.08.004
- ↑ De Matteis MA, Staiano L, Emma F, Devuyst O. The 5-phosphatase OCRL in Lowe syndrome and Dent disease 2. Nat Rev Nephrol. 2017 Aug;13(8):455-470. doi: 10.1038/nrneph.2017.83. Epub 2017, Jul 3. PMID:28669993 doi:http://dx.doi.org/10.1038/nrneph.2017.83
- ↑ 10.0 10.1 10.2 10.3 Hou X, Hagemann N, Schoebel S, Blankenfeldt W, Goody RS, Erdmann KS, Itzen A. A structural basis for Lowe syndrome caused by mutations in the Rab-binding domain of OCRL1. EMBO J. 2011 Mar 4. PMID:21378754 doi:10.1038/emboj.2011.60
- ↑ Choudhury R, Noakes CJ, McKenzie E, Kox C, Lowe M. Differential clathrin binding and subcellular localization of OCRL1 splice isoforms. J Biol Chem. 2009 Apr 10;284(15):9965-73. doi: 10.1074/jbc.M807442200. Epub 2009 , Feb 11. PMID:19211563 doi:http://dx.doi.org/10.1074/jbc.M807442200
- ↑ Sharma S, Skowronek A, Erdmann KS. The role of the Lowe syndrome protein OCRL in the endocytic pathway. Biol Chem. 2015 Dec;396(12):1293-300. doi: 10.1515/hsz-2015-0180. PMID:26351914 doi:http://dx.doi.org/10.1515/hsz-2015-0180
- ↑ Coon BG, Hernandez V, Madhivanan K, Mukherjee D, Hanna CB, Barinaga-Rementeria Ramirez I, Lowe M, Beales PL, Aguilar RC. The Lowe syndrome protein OCRL1 is involved in primary cilia assembly. Hum Mol Genet. 2012 Apr 15;21(8):1835-47. doi: 10.1093/hmg/ddr615. Epub 2012 Jan , 6. PMID:22228094 doi:10.1093/hmg/ddr615
- ↑ 14.0 14.1 14.2 Acosta-Tapia N, Galindo JF, Baldiris R. Insights into the Effect of Lowe Syndrome-Causing Mutation p.Asn591Lys of OCRL-1 through Protein-Protein Interaction Networks and Molecular Dynamics Simulations. J Chem Inf Model. 2020 Feb 24;60(2):1019-1027. doi: 10.1021/acs.jcim.9b01077., Epub 2020 Jan 30. PMID:31967472 doi:http://dx.doi.org/10.1021/acs.jcim.9b01077
- ↑ Ye Q, Shen Q, Rao J, Zhang A, Zheng B, Liu X, Shen Y, Chen Z, Wu Y, Hou L, Jian S, Wei M, Ma M, Sun S, Li Q, Dang X, Wang Y, Xu H, Mao J. Multicenter study of the clinical features and mutation gene spectrum of Chinese children with Dent disease. Clin Genet. 2020 Mar;97(3):407-417. doi: 10.1111/cge.13663. Epub 2020 Jan 13. PMID:31674016 doi:http://dx.doi.org/10.1111/cge.13663
- ↑ Pirruccello M, Swan LE, Folta-Stogniew E, De Camilli P. Recognition of the F&H motif by the Lowe syndrome protein OCRL. Nat Struct Mol Biol. 2011 Jun 12. doi: 10.1038/nsmb.2071. PMID:21666675 doi:10.1038/nsmb.2071
- ↑ Gianesello L, Del Prete D, Anglani F, Calo LA. Genetics and phenotypic heterogeneity of Dent disease: the dark side of the moon. Hum Genet. 2021 Mar;140(3):401-421. doi: 10.1007/s00439-020-02219-2. Epub 2020, Aug 29. PMID:32860533 doi:http://dx.doi.org/10.1007/s00439-020-02219-2
- ↑ Hichri H, Rendu J, Monnier N, Coutton C, Dorseuil O, Poussou RV, Baujat G, Blanchard A, Nobili F, Ranchin B, Remesy M, Salomon R, Satre V, Lunardi J. From Lowe syndrome to Dent disease: correlations between mutations of the OCRL1 gene and clinical and biochemical phenotypes. Hum Mutat. 2011 Apr;32(4):379-88. doi: 10.1002/humu.21391. Epub 2011 Mar 10. PMID:21031565 doi:10.1002/humu.21391